Orgalutran (Ganirelix)

Orgalutran is a GnRH antagonist used in fertility treatment protocols that control ovarian stimulation.

• Prevention of premature LH surge: Helps maintain timing of ovulation during IVF/ICSI cycles.
• Controlled ovarian hyperstimulation: Allows precise dosing of gonadotropins by preventing early luteinization.
• Assisted reproductive technology cycles: Supports the overall success of IVF and ICSI procedures.

• Ganirelix competitively binds to gonadotropin‑releasing hormone (GnRH) receptors in the pituitary gland, blocking the natural GnRH signal. This inhibition prevents the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby suppressing premature ovulation during controlled ovarian hyperstimulation.

Ganirelix is generally well tolerated, but injection site reactions and hormonal changes can occur.

Common Side Effects

• Injection site pain or erythema: Mild discomfort at the injection site.
• Headache: Transient headache without other neurological signs.
• Nausea: Mild, self‑limiting nausea.
• Fatigue: General tiredness that resolves spontaneously.
• Abdominal discomfort: Mild cramping or bloating.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): Severe fluid shift requiring medical attention.
• Allergic reaction: Rash, itching, swelling, or anaphylaxis.
• Severe abdominal pain: May indicate complications such as ovarian torsion.
• Thromboembolic events: Unusual clot formation.
• Hypersensitivity: Systemic signs of a severe allergic response.

When using Orgalutran, careful monitoring and adherence to clinical guidelines are essential.

• Patient selection: Confirm indication for assisted reproductive technology and assess baseline ovarian reserve.
• Monitoring: Perform regular ultrasound and hormone assessments during stimulation.
• Contraindications: Do not use in women with known hypersensitivity to ganirelix or any excipients.
• Pregnancy status: Avoid use in confirmed pregnancy; the drug is intended for use before ovulation.
• Drug interactions: Review concomitant medications that may affect hormonal balance.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Ganireblox may interact with other hormonal agents used in fertility protocols; awareness of these interactions helps maintain treatment efficacy.

Major Interactions (Avoid)

• GnRH agonists: Concurrent use can negate antagonist effect.
• High‑dose estrogen therapy: May alter hormonal feedback mechanisms.

Moderate Interactions (Monitor Closely)

• Anticoagulants: Monitor coagulation parameters if patient is on blood thinners.
• Corticosteroids: May require dose adjustment of gonadotropins.
• Antihistamines: May mask early signs of an allergic reaction.
• CYP450 inducers: Potentially reduce plasma levels of ganache.
• Herbal supplements: St. St